TROY CAR EXOs
Shine-On Biomedical Co., Ltd.
TROY CAR EXOs
Shine-On Biomedical Co., Ltd.
Back to Hall of Fame
Shine-On Biomedical is deploying and
engineering secreted extracellular vesicles
(EV) and exosomes, taking its natural
transmission advantages to develop an
entirely novel class of bio-therapeutics.
With a comprehensive intellectual property
portfolio creation including proprietary
manufacturing, purification, and
preservation methods, as well as a clinical
translation platform establishment, Shine-
On Biomedical’s EV novel therapeutics,
Troy-Exos, are engineered exosomes with
a safe and potent modality for precision
delivery of advanced payloads.
Troy-Exos owned a patented endogenous
immune checkpoint antibody and designed
a novel genetic engineering modification
method to fuse on the EV's membrane
proteins. Furthermore, they are loaded with
small molecules and nucleic acid drugs with
high efficiency. This nano-level immune
checkpoint nanobody acting as Troy-
Exos’ target is highly-expressed outside
the double-layer phospholipid layer of
exosomes, which increases the specificity
of exosomes to attack tumors instead of
normal tissue cells. In addition, Troy-Exos
with immune checkpoint nanobodies can
also prohibit the inhibitory effect of immune
cells caused by immune checkpoint antigens
after binding to tumor cells, thus increasing
the killing of tumor cells by T cells.
Highlights
- Presents a novel and unique concept of next-generation anticancer therapeutics.
- Solves the current problems of “nucleic acid therapeutics” packaging carriers in cancer treatment.
- Benefits patients by reducing unwanted side effects of drugs and improving therapeutic efficacy for late-stage cancer patients and patients’ quality of life.
View Website
Back to Hall of Fame
Shine-On Biomedical is deploying and
engineering secreted extracellular vesicles
(EV) and exosomes, taking its natural
transmission advantages to develop an
entirely novel class of bio-therapeutics.
With a comprehensive intellectual property
portfolio creation including proprietary
manufacturing, purification, and
preservation methods, as well as a clinical
translation platform establishment, Shine-
On Biomedical’s EV novel therapeutics,
Troy-Exos, are engineered exosomes with
a safe and potent modality for precision
delivery of advanced payloads.
Troy-Exos owned a patented endogenous
immune checkpoint antibody and designed
a novel genetic engineering modification
method to fuse on the EV's membrane
proteins. Furthermore, they are loaded with
small molecules and nucleic acid drugs with
high efficiency. This nano-level immune
checkpoint nanobody acting as Troy-
Exos’ target is highly-expressed outside
the double-layer phospholipid layer of
exosomes, which increases the specificity
of exosomes to attack tumors instead of
normal tissue cells. In addition, Troy-Exos
with immune checkpoint nanobodies can
also prohibit the inhibitory effect of immune
cells caused by immune checkpoint antigens
after binding to tumor cells, thus increasing
the killing of tumor cells by T cells.
Highlights
- Presents a novel and unique concept of next-generation anticancer therapeutics.
- Solves the current problems of “nucleic acid therapeutics” packaging carriers in cancer treatment.
- Benefits patients by reducing unwanted side effects of drugs and improving therapeutic efficacy for late-stage cancer patients and patients’ quality of life.